JP5926821B2 - 2−アリールベンゾフラン−7−カルボキサミド系化合物、その製造方法および用途 - Google Patents

2−アリールベンゾフラン−7−カルボキサミド系化合物、その製造方法および用途 Download PDF

Info

Publication number
JP5926821B2
JP5926821B2 JP2014555927A JP2014555927A JP5926821B2 JP 5926821 B2 JP5926821 B2 JP 5926821B2 JP 2014555927 A JP2014555927 A JP 2014555927A JP 2014555927 A JP2014555927 A JP 2014555927A JP 5926821 B2 JP5926821 B2 JP 5926821B2
Authority
JP
Japan
Prior art keywords
compound
group
methyl
mmol
esi
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014555927A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015511942A (ja
Inventor
ヤン,チュンハオ
ミャオ,ツェーホン
ディン,ジャン
ワン,メン
ヘー,ジンスエ
タン,チュン
チェン,イー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cisen Pharmaceutical Co Ltd
Shanghai Institute of Materia Medica
Original Assignee
Cisen Pharmaceutical Co Ltd
Shanghai Institute of Materia Medica
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cisen Pharmaceutical Co Ltd, Shanghai Institute of Materia Medica filed Critical Cisen Pharmaceutical Co Ltd
Publication of JP2015511942A publication Critical patent/JP2015511942A/ja
Application granted granted Critical
Publication of JP5926821B2 publication Critical patent/JP5926821B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/81—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/08—Preparation of carboxylic acid esters by reacting carboxylic acids or symmetrical anhydrides with the hydroxy or O-metal group of organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
    • C07C67/307—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of halogen; by substitution of halogen atoms by other halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2014555927A 2012-02-09 2013-01-14 2−アリールベンゾフラン−7−カルボキサミド系化合物、その製造方法および用途 Active JP5926821B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201210028895.0A CN103242273B (zh) 2012-02-09 2012-02-09 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途
CN201210028895.0 2012-02-09
PCT/CN2013/070410 WO2013117120A1 (zh) 2012-02-09 2013-01-14 2-芳基苯并呋喃-7-甲酰胺类化合物、其制备方法及用途

Publications (2)

Publication Number Publication Date
JP2015511942A JP2015511942A (ja) 2015-04-23
JP5926821B2 true JP5926821B2 (ja) 2016-05-25

Family

ID=48922178

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014555927A Active JP5926821B2 (ja) 2012-02-09 2013-01-14 2−アリールベンゾフラン−7−カルボキサミド系化合物、その製造方法および用途

Country Status (8)

Country Link
US (1) US9533965B2 (cg-RX-API-DMAC7.html)
EP (1) EP2813495B1 (cg-RX-API-DMAC7.html)
JP (1) JP5926821B2 (cg-RX-API-DMAC7.html)
CN (1) CN103242273B (cg-RX-API-DMAC7.html)
BR (1) BR112014019402B1 (cg-RX-API-DMAC7.html)
CA (1) CA2863988C (cg-RX-API-DMAC7.html)
RU (1) RU2583900C2 (cg-RX-API-DMAC7.html)
WO (1) WO2013117120A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用
MX2015006780A (es) 2012-12-31 2015-08-06 Cadila Healthcare Ltd Derivados de ftalazin-1-(2h)-ona sustituida.
CN105272936B (zh) * 2014-05-27 2019-05-17 中国科学院上海药物研究所 一类氮芳基苯并噻唑类parp抑制剂及其制备方法和用途
CN109134409B (zh) 2017-06-14 2023-09-29 中国科学院上海药物研究所 盐酸美呋哌瑞多晶型物及其制备方法与应用
CN111320596B (zh) * 2018-12-14 2024-07-05 甫康(上海)健康科技有限责任公司 盐酸美呋哌瑞多晶型物及其制备方法
JP7805005B2 (ja) * 2019-12-31 2026-01-23 フーカン(シャンハイ) ヘルス テクノロジー カンパニー、 リミテッド 腫瘍治療の医薬組み合わせとその使用
US20240016775A1 (en) 2020-02-24 2024-01-18 Fukang (Shanghai) Health Technology Co., Ltd Anti-coronavirus application of poly adp ribose polymerase inhibitor
EP4682143A1 (en) 2023-03-10 2026-01-21 Convalife Pharmaceuticals Co., Ltd. Pharmaceutical composition containing egfr inhibitor, and preparation method therefor and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL87451A0 (en) 1987-09-04 1989-01-31 Tanabe Seiyaku Co Benzofuran derivatives,their preparation and pharmaceutical compositions containing them
JP2002515488A (ja) * 1998-05-15 2002-05-28 ギルフォード ファーマシューティカルズ インコーポレイテッド カルボキサミド化合物、組成物、及びparp活性の抑制方法
TR200101239T2 (tr) * 1998-11-03 2001-11-21 Basf Aktiengesellschaft İkameli-2-fenilbenzimidazoller, üretimleri ve kullanımları
JP2002529537A (ja) * 1998-11-17 2002-09-10 ビーエーエスエフ アクチェンゲゼルシャフト 2−フェニルベンズイミダゾールおよび2−フェニルインドール、その製造方法ならびに使用
DE10022925A1 (de) * 2000-05-11 2001-11-15 Basf Ag Substituierte Indole als PARP-Inhibitoren
US7435837B2 (en) * 2003-10-24 2008-10-14 Wyeth Dihydrobenzofuranyl alkanamine derivatives and methods for using same
DE10351315A1 (de) 2003-10-31 2005-06-16 Aventis Pharma Deutschland Gmbh 2-Phenyl-benzofuran-Derivate, Verfahren zur ihrer Herstellung und ihre Verwendung
CA2580833C (en) * 2004-09-22 2010-12-21 Pfizer, Inc. Method of preparing poly(adp-ribose) polymerases inhibitors
JP5162465B2 (ja) * 2005-11-15 2013-03-13 アボット・ラボラトリーズ 置換1h−ベンズイミダゾール−4−カルボキサミド類は強力なparp阻害薬である
MX2008014004A (es) * 2006-05-02 2008-11-12 Abbott Lab 1h-benzimidazol-4-carboxamidas sustituidas son inhibidores de parp potentes.
MX347085B (es) * 2006-12-28 2017-04-06 Abbott Laboratories * Inhibidores de la poli (adp-ribosa) polimerasa.
JP2010518146A (ja) 2007-02-16 2010-05-27 グラクソ グループ リミテッド ベンゾフラン化合物
US20090010884A1 (en) * 2007-07-06 2009-01-08 Wyeth Pharmaceutical compositions and methods of preventing, treating, or inhibiting inflammatory diseases, disorders, or conditions of the skin, and diseases, disorders, or conditions associated with collagen depletion
CN101998959B (zh) * 2008-02-06 2013-08-28 生物马林药物股份有限公司 聚(adp-核糖)聚合酶(parp)的苯并噁唑甲酰胺抑制剂
GB0806656D0 (en) 2008-04-11 2008-05-14 Karobio Ab Novel estrogen receptor ligands
US8569336B2 (en) * 2008-11-10 2013-10-29 Ling Tong Compounds for the treatment of inflammatory disorders
US8476309B2 (en) 2009-08-20 2013-07-02 The University Of Tennessee Research Foundation Benzofuran cannabinoid compounds and related methods of use
GB0919380D0 (en) 2009-11-04 2009-12-23 Almac Discovery Ltd Pharmaceutical compouds
CN102627620B (zh) * 2012-04-10 2015-12-16 江苏先声药物研究有限公司 一类苯并呋喃衍生物及其医药应用

Also Published As

Publication number Publication date
RU2014132159A (ru) 2016-03-27
CN103242273B (zh) 2015-06-03
BR112014019402A8 (pt) 2017-07-11
US20150018542A1 (en) 2015-01-15
BR112014019402A2 (cg-RX-API-DMAC7.html) 2017-06-20
WO2013117120A1 (zh) 2013-08-15
RU2583900C2 (ru) 2016-05-10
BR112014019402B1 (pt) 2020-12-15
EP2813495A4 (en) 2015-06-17
JP2015511942A (ja) 2015-04-23
EP2813495B1 (en) 2016-09-28
CA2863988A1 (en) 2013-08-15
CA2863988C (en) 2016-03-22
US9533965B2 (en) 2017-01-03
CN103242273A (zh) 2013-08-14
EP2813495A1 (en) 2014-12-17

Similar Documents

Publication Publication Date Title
JP2015511942A (ja) 2−アリールベンゾフラン−7−カルボキサミド系化合物、その製造方法および用途
CN102378753B (zh) 纤溶酶原激活物抑制因子-1抑制剂
KR100618074B1 (ko) 벤즈아미드 유도체 및 이것의 사이토킨 억제제로서 용도
CN113181339B (zh) 一种醛基类化合物的药物用途
CN105037355A (zh) Wnt信号传导途径的吲唑抑制剂及其治疗用途
WO2008059867A1 (en) Novel 1,2-dihydroquinoline derivative having (substituted phenyl or substituted heterocyclic) carbonyloxy lower alkyl group and ester-introduced phenyl group as substituents
KR20090083491A (ko) 2-퓨란 카르복시산 하이드라지드 화합물 및 그것을 함유하는 의약 조성물
WO2002006264A1 (en) Lipid-rich plaque inhibitors
TW200417546A (en) New compounds
CN103842350B (zh) 作为dhodh抑制剂的五元二氢杂环酮类衍生物及应用
Schuler et al. Boronic acid-containing aminopyridine-and aminopyrimidinecarboxamide CXCR1/2 antagonists: Optimization of aqueous solubility and oral bioavailability
CN108069954B (zh) 含no供体的喹唑啉酮化合物
CN102993093A (zh) N,n’-二取代二苯基硫脲类化合物、其制备方法和用途
WO2024040768A1 (zh) 5-吡啶-1h-吲唑类化合物、药物组合物和应用
JPWO2003011812A1 (ja) ヒト−β−トリプターゼ阻害活性を有する新規アミン誘導体およびそれを含有する医薬
CN101544631B (zh) 吡唑类5-脂氧酶小分子抑制剂及其制备方法、药物组合物和应用
CN110099685A (zh) 溴结构域抑制剂
EP3684354B1 (en) Xpa inhibitor compounds and their use
CN104945411A (zh) 噻吩并[3,2-c]吡啶类化合物、其制备方法及应用
CN102532113B (zh) 芳基脲衍生物
CN111018686B (zh) 6-苄亚基-2-芳基乙炔基环己烯酮衍生物及其制备方法和医药用途
WO2012174926A1 (zh) N-取代异丙二甲薁磺酰胺类衍生物及其制备方法和用途
US20090030049A1 (en) Medicament for genital herpes
CN104370890B (zh) 一类喹唑啉类化合物及其作为免疫抑制剂的应用
CN112236414A (zh) 促分裂原活化蛋白激酶7抑制剂

Legal Events

Date Code Title Description
A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20151030

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160225

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160412

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160422

R150 Certificate of patent or registration of utility model

Ref document number: 5926821

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250